By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1 DNA Way

South San Francisco  California  94080-4990  U.S.A.
Phone: 650-225-1000 Fax: 650-225-6000

Since 2005, Genentech has been expanding its facilities in Oceanside, about 35 miles north of San Diego. Today, the campus spans 60 acres and includes a multi-product, biotech manufacturing and clinical operations complex with six buildings totaling 500,000 square feet. Upon receiving U.S. Food and Drug Administration licensure in 2007, the Oceanside facility added 90,000 liters of capacity that are now approved for the production of Rituxan and Avastin bulk drug substance.

On the Southern California Coast, halfway between Los Angeles and San Diego, Oceanside is a beautiful beachfront community of roughly 200,000 people. As one of Oceanside’s largest employers, Genentech takes great pride in the impact we have on the community, but also in the impact the community has on our employees.

Please view our company video on YouTube:

Connect with us via Social Media:




Key Statistics

Ownership: Subsidiary

Web Site: Genentech
Employees: 10,000+
Symbol: RHHBY



Company News
Tennessee Oncology Sues Genentech (RHHBY) Over Cancer Drug Herceptin 2/9/2016 6:45:05 AM
Biopharma Business Grad Hiring Is Up, with Johnson & Johnson (JNJ), Eli Lilly (LLY), Bayer (BAY) and Genentech (RHHBY) Leading the Way 1/25/2016 6:32:16 AM
Genentech (RHHBY) Sponsored Study Reveals Hidden Stigma of Lung Cancer 1/21/2016 10:18:42 AM
Denali, Helmed by Former Genentech (RHHBY) Execs, Takes Space in South San Francisco Site 1/18/2016 6:31:47 AM
Genentech (RHHBY) Release: FDA Grants Priority Review For Venetoclax New Drug Application 1/12/2016 7:39:21 AM
Genentech (RHHBY) Touts Hematology Data for Gazyva and Venetoclax in CLL 12/16/2015 11:06:58 AM
Genentech (RHHBY) Wins Accelerated Approval for Alecensa to Treat Specific Lung Cancer Patients 12/11/2015 11:48:06 AM
Genentech (RHHBY) Release: Pivotal Phase II Study Showed Nearly 80 Percent Of People With Hard-To-Treat Type Of Chronic Lymphocytic Leukemia Responded To Investigational Medicine Venetoclax 12/7/2015 1:30:11 PM
Genentech (RHHBY) Release: New Results From CLL11 Study Show Gazyva Provided People With Previously Untreated Chronic Lymphocytic Leukemia A Treatment-Free Period Of Nearly Four Years 12/7/2015 12:50:27 PM
Genentech (RHHBY) Release: Updated Data Showed Cotellic In Combination With Zelboraf Helped People With A Specific Type Of Advanced Melanoma Live Significantly Longer Than With Zelboraf Alone 11/23/2015 9:57:33 AM